{
  "id": 4858304,
  "title": "Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating",
  "url": "https://urgent.news/2026/09/01/chardan-assumes-rocket-pharmaceuticals-stock-coverage-with-buy-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-01T12:22:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/chardan-assumes-rocket-pharmaceuticals-stock-coverage-with-buy-rating-93CH-4884006"
  },
  "original_language": "en",
  "account": "Investing.com has announced that Chardan has taken over Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) as a client, assigning the stock a Buy rating and setting a price target of $11.00. Analyst Keay Nakae is now responsible for covering the gene therapy company, retaining the previous Buy rating and $11 price target. Rocket Pharmaceuticals is currently trading at $3.72, indicating significant potential for upside from the analyst's target. The company is in the process of developing three AAV-based cardiovascular programs in clinical stages and has an FDA-approved ex vivo lentiviral gene therapy, Kresladi, for severe leukocyte adhesion deficiency-I.\n\nRocket Pharmaceuticals recently monetized the Kresladi Priority Review Voucher for $180 million in June 2026, raising the company's cash reserves to $283.7 million as of the quarter-end. This financial strength, complemented by a robust current ratio of 9.24, underscores the company's stability. However, Rocket is experiencing cash burn as it focuses on its near-term drug candidate RP-A501 for Danon disease. The company is actively communicating with the FDA regarding the next steps for the remainder of the trial.\n\nIn a separate development, TD Cowen has maintained a Hold rating on Rocket Pharmaceuticals' stock, driven by safety concerns regarding the RP-A501 gene therapy for Danon disease. Following a clinical hold placed on the program, Tara Bancroft, an analyst from TD Cowen, expressed that safety emerged as a key issue. Yet, no safety events were observed in the first three patients treated at a recalibrated dose, providing a glimmer of optimism for the company's ongoing gene therapy advancements.",
  "summary": null,
  "key_points": [
    "Chardan takes over Rocket Pharmaceuticals coverage with Buy rating.",
    "Analyst Keay Nakae retains Buy rating and $11 price target.",
    "Rocket Pharmaceuticals develops three AAV-based cardiovascular programs."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}